BridgeMD
A Study of REGN7041 for Active Noninfectious Uveitis in Adult Participants
EU CTIS ID: 2025-521713-57-00
What this study is testing
To evaluate the ocular and systemic safety and tolerability of single and repeated doses of intravitreally administered REGN7041 in participants with active NIU-PS.
- Phase I and Phase II (Integrated)- First administration to humans
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Diagnosis of non-infectious anterior, intermediate, posterior or panuveitis, (For anterior uveitis, there must be evidence of inflammation affecting the posterior segment), as defined in the protocol
- Active disease at baseline, as defined in the protocol
- Part A only: Best Corrected Visual Acuity (BCVA) of ≤65 and >10 Early Treatment Diabetic Retinopathy Study (ETDRS) letters (Snellen equivalent of worse than or equal to 20/50 and better than 20/630) at the screening visit and on day 1
- Part B only: BCVA of <75 and >10 ETDRS letters (Snellen equivalent of worse than 20/32 and better than 20/630) at the screening visit and on day 1
You likely can't join if
- BCVA of ≤30 ETDRS letters (Snellen equivalent of 20/250 or worse) at the screening visit and/or on day 1
- Intraocular Pressure (IOP) <5 mm Hg at the screening visit and/or on day 1
- IOP >25 mm Hg on day 1. Participants are permitted to take IOP-lowering eye drops
- Confirmed or suspected infectious uveitis, as defined in the protocol. NOTE: Other Protocol-Defined Inclusion/Exclusion Criteria Apply
The study team makes the final eligibility decision.
Where it's taking place
- United Kingdom
- United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include United Kingdom; United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.